Therapy or antidepressants? Coming soon: Brain activity “fingerprints” to personalize depression treatments

. To Treat Depres­sion, Drugs or Ther­a­py? (The New York Times): “Until recent­ly, many experts thought that your clin­i­cian could lit­er­al­ly pick any anti­de­pres­sant or type of psy­chother­a­py at ran­dom because, with a few clin­i­cal excep­tions, there was lit­tle evi­dence to favor one treat­ment over anoth­er for a giv­en patient

Read More

Update: Let’s transform brain health from “suffer-in-silence” to “let-me-take-control”

Time for our Sep­tem­ber 2014 e‑newsletter, fea­tur­ing a wealth of insights  and inno­va­tions reports…including four thought-pro­­vok­ing inter­views with Spon­sors of the 2014 Sharp­Brains Vir­tu­al Sum­mit (Octo­ber 28–30th). Enjoy! New per­spec­tives at the fron­tier of Brain, Health & Inno­va­tion: Bar­bara Arrow­smith Young: Every kid should prac­tice stress reduc­tion and tar­get­ed cog­ni­tive exer­cis­es at school Michael Meagher (Cog­nic­i­ti): Let’s trans­form brain…

Read More

Three Ways to Bring Mindfulness Into Therapy

— Many ther­a­pists have come to regard cul­ti­vat­ing moment-to-moment aware­ness as a cura­tive mech­a­nism that tran­scends diag­no­sis, address­es under­ly­ing caus­es of suf­fer­ing, and serves as an active ingre­di­ent in most effec­tive psy­chother­a­pies. The clin­i­cal val­ue of 

Read More

Rethinking Alzheimer’s research, beyond amyloid deposition, via new funding models

How a new approach to fund­ing Alzheimer’s research could pay off (MIT News): “More than 5 mil­lion Amer­i­cans suf­fer from Alzheimer’s dis­ease, the afflic­tion that erodes mem­o­ry and oth­er men­tal capac­i­ties, but no drugs tar­get­ing the dis­ease have been approved by the U.S. Food and Drug Admin­is­tra­tion since 2003…Lo and three co-authors propose 

Read More